Targets and applications of nanodrug targeting myeloid cells in osteosarcoma for the enhancement of immunotherapy
Mechanism of Action of Nanoparticles Targeting Bone Marrow Cells in the Modulation of Immunotherapy After being phagocytosed by myeloid cells, nanoparticles can activate the STING signaling pathway in tumor-associated macrophages, thereby initiating cellular immunity. At the same time, they can release the carried LncRNA or miRNA to silence specific gene expressions, leading to a transformation in the macrophage subtype. Nanoparticles carrying specific ligands such as PD1, B7, and OX40 can bind to specific ligands on dendritic cells and M1-type macrophages, enhancing the antigen presentation ability of dendritic cells and M1-type macrophages and strengthening the specific immunity against tumor cells. Nanoparticles carrying chemotherapy drugs have a direct cytotoxic effect on tumor tissues, promoting immunogenic cell death (ICD) and thus enhancing the direct cytotoxic effects of T cells and NK cells on tumor cells. In addition, during blood transport, nanoparticles wrap Lipidosomes and PEG to reduce cytotoxic side effects on normal tissues, enhancing the specificity of immunotherapy.